Current status and impact of CMV prevention following pediatric organ transplantation.
Allen
Upton D
UD
D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D019468:Disease Management; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006084:Graft Rejection; D006801:Humans; D007107:Immune System; D008232:Lymphoproliferative Disorders / Q000517:prevention & control; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D016377:Organ Transplantation / Q000009:adverse effects / Q000379:methods*; D000077562:Valganciclovir
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir